 JUPITER, Fla., Aug. 11, 2021 GLOBE NEWSWIRE -- Dyadic International, Inc. Dyadic, we, us, our, or the Company NASDAQ: DYAI, a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, and Sorrento Therapeutics, Inc. Sorrento NASDAQ: SRNE, a clinical stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, today announced the signing of a binding term sheet to enter into a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadics lead COVID-19 vaccine candidate, DYAI-100, produced using Dyadics proprietary and patented C1-cell protein production platform. The final terms of the license will be set forth in a definitive agreement to be entered into between the parties. 